Diamante Closes Euro 595,000 Seed Round Led by Arieli Capital
Summary
Diamante will use proceeds to scale into the US and begin an FDA approval processVERONA, Italy, Jan. 17, 2023 /PRNewswire/ -- , a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by . Offering value for global markets, Diamante is creating a groundbreaking health technology with the power to improve the health of millions of people around the world.Believing in the project, developed since 2020 by Roberta Zampieri, Valentina Garonzi and Linda Avesani, is also Elena Paola Lanati and associations Angels4Women and Angels4Impact as Business Angels, following the recent equity round of Euro 350,000 closed in July 2022.Diamante and its quotaholder were assisted in negotiating legal matters and contractual terms of both equity rounds by the law firm Legance Avvocati Associati, with a team consisting of partner Giacomo Gitti and associate Diego Valenti, as well as by Studio Marchiori for financial and tax issues, and by the Notary Lorenzo Salvatore.Diamante was founded in 2016 with the development of new tools in autoimmune disease diagnosis and is now expanding into therapeutics applications. Diamantes value proposition is the creation of a novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. We are happy to welcome Diamante to Arielis family of portfolio companies as it promotes our core values of advancing impact technologies, women led entrepreneurship and the great partnership with our Italian partners. Arielis 2-pronged investment structure, backed by our global innovation network and access to resources, provides consistent long-term value for our partners.